A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

Prediction of HER2 overexpression status and IHC score as seen in "Predicting the HER2 status in esophageal cancer from tissue microarrays using convolutional neural networks".

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment This retrospective ...

INDIANAPOLIS — JuJu Watkins’ glitzy offensive stats are enough to earn her national player of the year honors. It’s her defense that's going to make USC so dangerous heading into the NCAA ...

Check your free credit score and credit report as often as you want, and get alerts about changes so you can manage your credit effectively. Credit education Stay on top of your score with ...